BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22081542)

  • 1. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?
    Kiss LS; Papp M; Lovasz BD; Vegh Z; Golovics PA; Janka E; Varga E; Szathmari M; Lakatos PL
    Inflamm Bowel Dis; 2012 Sep; 18(9):1647-54. PubMed ID: 22081542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.
    Lakatos PL; Kiss LS; Palatka K; Altorjay I; Antal-Szalmas P; Palyu E; Udvardy M; Molnar T; Farkas K; Veres G; Harsfalvi J; Papp J; Papp M
    Inflamm Bowel Dis; 2011 Mar; 17(3):767-77. PubMed ID: 20865702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plateletcrit: a sensitive biomarker for evaluating disease activity in Crohn's disease with low hs-CRP.
    Tang J; Gao X; Zhi M; Zhou HM; Zhang M; Chen HW; Yang QF; Liang ZZ
    J Dig Dis; 2015 Mar; 16(3):118-24. PubMed ID: 25565427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study.
    Kwon JH; Im JP; Ye BD; Cheon JH; Jang HJ; Lee KM; Kim YS; Kim SW; Kim YH; Song GA; Han DS; Kim WH; Kim JS
    Gut Liver; 2016 Jul; 10(4):595-603. PubMed ID: 27021506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.
    Lakatos PL; Czegledi Z; Szamosi T; Banai J; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp J; Lakatos L
    World J Gastroenterol; 2009 Jul; 15(28):3504-10. PubMed ID: 19630105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sinus rhythm restoration on high-sensitivity C-reactive protein levels and their association with long-term atrial fibrillation recurrence after electrical cardioversion.
    Celebi OO; Celebi S; Canbay A; Ergun G; Aydogdu S; Diker E
    Cardiology; 2011; 118(3):168-74. PubMed ID: 21654170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease.
    Oh K; Oh EH; Baek S; Song EM; Kim GU; Seo M; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    PLoS One; 2017; 12(6):e0179266. PubMed ID: 28622356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation.
    Bhattacharya A; Rao BB; Koutroubakis IE; Click B; Vargas EJ; Regueiro M; Schwartz M; Swoger JM; Babichenko D; Hartmann D; Rivers CR; Barrie A; Hashash JG; Dunn MA; Binion DG
    Inflamm Bowel Dis; 2016 Nov; 22(11):2665-2671. PubMed ID: 27753691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Albumin and C-Reactive Protein/Albumin Ratio Are Useful Biomarkers of Crohn's Disease Activity.
    Qin G; Tu J; Liu L; Luo L; Wu J; Tao L; Zhang C; Geng X; Chen X; Ai X; Shen B; Pan W
    Med Sci Monit; 2016 Nov; 22():4393-4400. PubMed ID: 27848931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Fecal Inflammatory Markers in Crohn's Disease.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Keenan JI; Leach S; Burgess L; Aitchison A; Gorelik A; Liew D; Day AS; Gearry RB
    Inflamm Bowel Dis; 2016 May; 22(5):1086-94. PubMed ID: 26818420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically active Crohn's disease in the presence of a low C-reactive protein.
    Florin TH; Paterson EW; Fowler EV; Radford-Smith GL
    Scand J Gastroenterol; 2006 Mar; 41(3):306-11. PubMed ID: 16497618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease.
    Chamouard P; Richert Z; Meyer N; Rahmi G; Baumann R
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):882-7. PubMed ID: 16630759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
    Schaffer T; Schoepfer AM; Seibold F;
    J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn's disease from intestinal lymphoma, intestinal tuberculosis and Behcet's syndrome.
    Liu S; Ren J; Xia Q; Wu X; Han G; Ren H; Yan D; Wang G; Gu G; Li J
    Am J Med Sci; 2013 Dec; 346(6):467-72. PubMed ID: 23689052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.